RxDoctor Payments Data

Christopher Hebert, MD

Nephrology · Dallas, TXNPI 1912966045

Payments from drug & device makers

$101,515in general payments, 2019–2025

Across 285 payments — averaging $356.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$60K
  • Mallinckrodt Enterprises LLC$19K
  • Nxstage Medical, Inc.$18K
  • La Jolla Pharmaceutical Company$2K
  • Vifor Pharma, Inc.$536
  • Amgen$378
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$5,4655%
  • Speaking & faculty fees$83,76183%
  • Travel & lodging$5,0145%
  • Food & beverage$7,2557%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,515 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$4,345
Medicare patients
12
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$65,163
JardianceEmpagliflozin18$28,388
EliquisApixaban19$27,063
FarxigaDapagliflozin Propanediol16$13,821
OzempicSemaglutide16$13,745
EntrestoSacubitril/Valsartan15$9,787
Ezetimibe63$1,875
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$1,856
Rosuvastatin Calcium77$1,189
Colchicine11$1,009
Amlodipine Besylate78$896
Losartan Potassium72$723
Levothyroxine Sodium44$675
Duloxetine Hcl18$527
Allopurinol49$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$28,38818 claims
PfizerEliquis$138$27,06319 claims
AstraZenecaFarxiga$60,307$13,82116 claims
ANI Pharmaceuticals, Inc.Valsartan$85$49714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →